CoreCap Advisors
PCVX icon

CoreCap Advisors’s Vaxcyte PCVX Stock Holding History

CoreCap Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$455 Hold
8
– – ﹤0.01% 2826
2026
Q2 		$465 Hold
8
– – ﹤0.01% 2875
2026
Q1 		$465 Hold
8
– – ﹤0.01% 2662
2025
Q4 		$369 Hold
8
– – ﹤0.01% 2743
2025
Q3 		$288 Hold
8
– – ﹤0.01% 2633
2025
Q2 		$260 Hold
8
– – ﹤0.01% 2592
2025
Q1 		$302 Hold
8
– – ﹤0.01% 2812
2024
Q4 		$655 Buy
+8
New +$794 ﹤0.01% 2445

Other funds holding PCVX

Banque Pictet & Cie
Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return
Inspire Investing
Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return
Avior Wealth Management
Avior Wealth Management Omaha, Nebraska $3.79B AUM 15.36% 1-Year Est. Return
Values First Advisors
Values First Advisors Gray, Tennessee $213M AUM 20.51% 1-Year Est. Return
Teza Capital Management
Teza Capital Management Chicago, Illinois $112M AUM 57.58% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

CoreCap Advisors's PCVX Position: Q3 2026 in Review

CoreCap Advisors held its Vaxcyte (PCVX) position steady in Q3 2026 at 8 shares worth $455. The position accounts for ﹤0.01% of the portfolio, ranked #2826.

CoreCap Advisors first reported a position in PCVX in Q4 2024 and has held it in 8 quarters since. The position peaked at $655 in Q4 2024. 41 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

  • CoreCap Advisors held 8 shares of Vaxcyte worth $455 as of Q3 2026.
  • CoreCap Advisors left its Vaxcyte share count unchanged in Q3 2026.
  • Vaxcyte made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #2826 holding.
  • CoreCap Advisors first reported a position in Vaxcyte in Q4 2024 and has held it in 8 quarters since.
  • CoreCap Advisors's Vaxcyte position peaked at $655 in Q4 2024.
  • 41 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.